In vitro: In contrast to SK-N-BE(2) cells, co-treatment of IMR-32 cells with TTFA not only failed to stimulate formation of ROS produced by cisplatin, but rather suppressed it. This correlates with the attenuation of the caspase-3-like activity in response to combined treatment of IMR-32 cells with TTFA and cisplatin.
In vivo: TTFA-mediated inhibition of the ubiquinone-binding site of SDHD blocks electron transfer to ubiquinone and may lead to electron-slippage with the formation of superoxide radicals, thereby contributing to ROS production.
|Cell lines||NB cell lines|
|Preparation method||For the time lapse, cells were cultivated in the POC-R cell cultivation system at 37 °C and a humidified air/CO2 (5%) atmosphere. Cisplatin ± TTFA was bath-applied before the start of the time lapse and the fluorescence was recorded for 22 h.|
|Concentrations||75 μM, 100 μM|
|Incubation time||24 h|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
Targeting succinate:ubiquinone reductase potentiates the efficacy of anticancer therapy.
Kruspig B, et al. Biochim Biophys Acta. 2016 Aug;1863(8):2065-71. PMID: 27140478.
Ubiquinone-binding site mutagenesis reveals the role of mitochondrial complex II in cell death initiation
K Kluckova, et al. Cell Death Dis. 2015 May;6(5): e1749. PMID: 25950479.
AM-0902 is a potent, selective antagonist of TRPA1 with IC50s of 71 and 131 nM for rTRPA1 and hTRPA1, respectively.
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical development for cardiovascular.
BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor.
VU6005649 is a CNS penetrant mGlu7/8 receptor agonist with EC50s of 0.65 μM and 2.6 μM for mGlu7 receptor and mGlu8 receptor, respectively.
TLR7-agonist-1 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.